CTI BioPharma : FDA Approves VONJO To Treat Myelofibrosis And Thrombocytopenia In Adults
1/3 02:44
(RTTNews) - CTI BioPharma Corp. (CTIC) said Monday that the U.S. Food and Drug Administration has approved VONJO or pacritinib for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis...